February 16, 2017-- Newly released findings from national HIV surveys in Zimbabwe, Malawi, and Zambia reveal extraordinary progress in confronting the HIV epidemic. These three countries in Southern Africa have been heavily affected by HIV, and now there are encouraging signs that the epidemics are going in the right direction.
The findings, presented today at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), are from the PEPFAR-supported Population-based HIV Impact Assessment (PHIA) Project surveys. The surveys are led by each Ministry of Health, with technical assistance from ICAP at Columbia University's Mailman School of Public Health in collaboration with the U.S. Centers for Disease Control and Prevention (CDC). Compared with previous estimates, the PHIA data show that the rate of new infections (incidence) is stabilizing or declining. In addition, more than half of all adults living with HIV, regardless of use of antiretroviral medication, have a suppressed viral load and for those on antiretroviral medication, viral suppression is close to 90 percent. "Taken together, these findings tell a coherent and remarkable story of progress," said Dr. Jessica Justman, principal investigator and associate professor of Epidemiology at the Mailman School of Public Health. "We can see that Zimbabwe, Malawi and Zambia are on track to hit the UNAIDS 90-90-90 targets by 2020."
Understanding the true status of an HIV epidemic rests on accurate measures of HIV prevalence, HIV incidence, and viral load suppression. These critical estimates provide a "report card" on the control of the epidemic and indicate where resources should be channeled to enable continued progress toward the 90-90-90 targets. The PHIA Project provides such information by directly assessing all of these measures through household surveys.
"These results are gratifying evidence that the investment by PEPFAR and other donors, and the efforts of national HIV programs, are paying off. The data from the PHIA surveys provide greater insights on where to focus our collective efforts and resources going forward," said Dr. Shannon Hader, director of the Division of Global HIV and Tuberculosis at CDC.
In Malawi, Zambia, and Zimbabwe, nationally representative groups of adults and children were recruited in each country in 2015-16. Across the three countries, a total of 76,000 adults and children from 34,000 selected households took part in interviews and provided blood samples for testing. Participants received their HIV test result from a trained counselor during the same visit.
Combined HIV prevalence across the three countries was 12.2 percent among adults ages 15-59 years and 1.4 percent among children ages 0-14 years. Combined HIV incidence among adults was 0.51 percent. The combined prevalence of viral suppression (HIV RNA <1000 c/ml) among all HIV-positive adults, irrespective of knowledge of their HIV status, was 61.8 percent. Achievement of the "first 90 target" across the three countries--i.e., prior knowledge of status among those found to be HIV-positive during the survey--was 70 percent; the "second 90 target"--i.e., the percentage of those aware of their HIV-positive status who report current use of antiretroviral therapy (ART)--was 87 percent; and the "third 90 target"--i.e., the percentage among those who report current ART who had HIV viral suppression--was 89 percent. Less progress has been made toward the 90-90-90 targets among adolescents and young adults compared to older adults.
"These results reflect successful HIV care and treatment programs in each country," said Dr. Wafaa El-Sadr, Director of ICAP and University Professor of Epidemiology and Dr. Mathilde Krim-amfAR Chair of Global Health at the Mailman School of Public Health. "Now more than ever, we have to keep our foot on the pedal and push even harder. Targeted testing, especially for adolescents and young adults, and continued expansion of HIV treatment programs and other prevention interventions for all will be critical to achieve ultimate epidemic control."
###
For more information, see the PHIA Project website: phia.icap.columbia.edu.
About the PHIA Project
The PHIA Project is a five-year, multi-country initiative funded by U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC), and conducted by ICAP at Columbia University, CDC, and local governmental and nongovernmental partners. The PHIA Project consists of household-based, population surveys that will collect information related to HIV in 13 countries.
This project is supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement #U2GGH001226. The contents are the responsibility of ICAP and do not necessarily reflect the views of the United States Government.
About ICAP
ICAP was founded in 2003 at Columbia University's Mailman School of Public Health. Now a global leader in HIV and health systems strengthening, ICAP provides technical assistance and implementation support to governments and non-governmental organizations in more than 21 countries. ICAP has supported work at more than 5,300 health facilities around the world. More than 2.3 million people have received HIV care through ICAP-supported programs and over 1.3 million have begun antiretroviral therapy. Online at icap.columbia.edu
Columbia University's Mailman School of Public Health
Founded in 1922, Columbia University's Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master's and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP (formerly the International Center for AIDS Care and Treatment Programs) and the Center for Infection and Immunity. For more information, please visit http://www.mailman.columbia.edu.